Quantcast

Latest Ibritumomab tiuxetan Stories

2008-11-03 09:00:39

Cephalon, a biopharmaceutical company, has announced that the FDA has approved Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. According to the company, the data supporting the FDA approval show that Treanda is effective, has a tolerable side effect profile in patients with indolent non-Hodgkin's lymphoma (NHL) and that treatment...

2008-10-27 09:00:11

Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that Rituxan(R) (rituximab) data including results from Phase II and III studies of Rituxan in patients with moderately-to-severely active rheumatoid arthritis (RA) will be featured in two podium presentations and eight poster presentations at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco this week. Among the studies being presented are a Phase III controlled re-treatment...

2008-10-22 09:00:42

Tracon Pharmaceuticals, a biopharmaceutical company developing targeted therapies for cancer and eye diseases, has appointed Bryan Leigh its new chief medical officer. Dr Leigh has previously served as chief medical officer for Paramount Biosciences. Dr Leigh has also held positions at Genentech, Idec Pharmaceuticals, and Biogen Idec where he was responsible for global clinical oncology development, managing multiple clinical stage programs and marketed products including Rituxan and...

2008-10-21 09:00:53

SAN DIEGO, Oct. 21, 2008 (GLOBE NEWSWIRE) -- Tracon Pharmaceuticals, Inc., a biopharmaceutical company developing targeted therapies for cancer and eye diseases, today announced the appointment of Bryan Leigh, M.D. as Chief Medical Officer. Dr. Leigh previously served as Chief Medical Officer for Paramount Biosciences. He has also held positions at Genentech, IDEC Pharmaceuticals, and Biogen Idec where he was responsible for global clinical oncology development, managing multiple clinical...

2008-10-20 03:00:08

SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of an innovative study that investigated high (bone marrow ablative) dose Zevalin(R) ([90Y]-ibritumomab tiuxetan) followed by autologous stem cell infusions among 30 patients (median age 62 years) with relapsed/refractory or high risk aggressive non-Hodgkin's lymphoma (NHL) not eligible for a chemotherapy-based...

2008-10-16 03:00:08

SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free...

2008-10-07 09:00:55

Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for US...

2008-10-03 09:00:07

Cell Therapeutics, a biopharmaceutical company, has submitted a supplemental biologics license application to the FDA for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. If approved, Zevalin would be the only radioimmunotherapy in the US with approval for use as first-line consolidation therapy. The company has requested priority review, which if granted, would result in a six month review period....

2008-10-02 03:00:18

SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. If approved, Zevalin would be the only radioimmunotherapy in the U.S. with approval for...

2008-09-24 03:00:09

By DeNardo, Gerald Advances in imaging technology have made it possible to view molecular pathways within living individuals as never before. However, molecular imaging and therapy have existed for more than a half-century and are based on long-established concepts and methods (see suggested references for support for statements made in this commentary). As molecular techniques come to the forefront in medicine, it has become clear that, just as a diversity of scientists is required to...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin